These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1285 related items for PubMed ID: 19156838

  • 1. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT.
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [Abstract] [Full Text] [Related]

  • 2. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.
    BMC Med Genet; 2007 Jul 05; 8():43. PubMed ID: 17612397
    [Abstract] [Full Text] [Related]

  • 3. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossée M, Pagès M, Rivier F, Danos O, Garcia L, Claustres M.
    Hum Mutat; 2007 Feb 05; 28(2):196-202. PubMed ID: 17041910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
    Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, den Dunnen JT, Verbist BM, Bakker E, Verschuuren JJ, Ginjaar HB.
    Neuromuscul Disord; 2010 Apr 05; 20(4):251-4. PubMed ID: 20153965
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    Ann N Y Acad Sci; 2009 Sep 05; 1175():71-9. PubMed ID: 19796079
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J, Zhang C.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug 05; 28(4):406-8. PubMed ID: 21811980
    [Abstract] [Full Text] [Related]

  • 15. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    J Gene Med; 2009 Mar 05; 11(3):257-66. PubMed ID: 19140108
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ, Malerba A, Dickson G.
    Methods Mol Biol; 2012 Mar 05; 867():143-67. PubMed ID: 22454060
    [Abstract] [Full Text] [Related]

  • 19. Modification of pre-mRNA processing: application to dystrophin expression.
    Wilton SD, Fletcher S.
    Curr Opin Mol Ther; 2006 Apr 05; 8(2):130-5. PubMed ID: 16610765
    [Abstract] [Full Text] [Related]

  • 20. Induced dystrophin exon skipping in human muscle explants.
    McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD.
    Neuromuscul Disord; 2006 Oct 05; 16(9-10):583-90. PubMed ID: 16919955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.